U. Schmidt

发表

Systematic in vitro evaluation of survivin directed antisense oligodeoxynucleotides in bladder cancer cells.

M. Wirth, A. Meye, M. Kotzsch, 2004, The Journal of urology.

Microarray analyses in bladder cancer cells: inhibition of hTERT expression down-regulates EGFR.

M. Wirth, A. Meye, S. Fuessel, 2006, International journal of cancer.

Vascular endothelial growth factor antisense pretreatment of bladder cancer cells significantly enhances the cytotoxicity of mitomycin C, gemcitabine and Cisplatin.

M. Wirth, S. Krause, A. Meye, 2005, The Journal of urology.

Isolation and enrichment of urologic tumor cells in blood samples by a semi-automated CD45 depletion autoMACS protocol.

M. Wirth, H. Taubert, A. Meye, 2002, International journal of oncology.

Chemosensitization of bladder cancer cell lines by human telomerase reverse transcriptase antisense treatment.

M. Wirth, A. Meye, M. Kotzsch, 2004, The Journal of urology.

Microarray analyses in bladder cancer cells: Inhibition of hTERT expression down‐regulates EGFR

M. Wirth, A. Meye, S. Fuessel, 2006 .

Identification of a novel gene on chromosome 13 between BRCA‐2 and RB‐1

C. Pilarsky, G. Sauter, S. Füssel, 2001, The Prostate.

siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth.

M. Wirth, H. Taubert, A. Meye, 2004, International journal of oncology.

Quantitative multi‐gene expression profiling of primary prostate cancer

M. Wirth, A. Meye, G. Baretton, 2006 .

Quantitative multi-gene expression profiling of primary prostate cancer.

M. Wirth, A. Meye, G. Baretton, 2006, The Prostate.

Quantitative multi‐gene expression profiling of primary prostate cancer

M. Wirth, A. Meye, G. Baretton, 2006, The Prostate.

Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxynucleotides and siRNA

M. Wirth, A. Meye, M. Kotzsch, 2006 .

Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells.

M. Wirth, A. Meye, M. Kotzsch, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxynucleotides and siRNA.

M. Wirth, A. Meye, M. Kotzsch, 2005, Cancer letters.

Quantification of C13orf19/P38IP mRNA expression by quantitative real-time PCR in patients with urological malignancies.

M. Wirth, A. Meye, S. Fuessel, 2005, Cancer letters.

Functional analyses of C 13 orf 19 / P 38 IP in prostate cell lines

M. Wirth, A. Meye, S. Fuessel, 2022 .

Comparison of the Clinical Value of Complexed PSA and Total PSA in the Discrimination between Benign Prostatic Hyperplasia and Prostate Cancer

M. Wirth, A. Meye, O. Hakenberg, 2006, Urologia Internationalis.

Elevated expression level of survivin protein in soft-tissue sarcomas is a strong independent predictor of survival.

Matthias Bache, H. Taubert, A. Meye, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

LOH analyses in the region of the putative tumour suppressor gene C13 on chromosome 13q13.

M. Wirth, A. Meye, S. Füssel, 2001, Anticancer research.

Expression of the extracellular matrix signaling molecule Cyr61 is downregulated in prostate cancer

C. Pilarsky, M. Wirth, G. Faller, 1998, The Prostate.

Multiple tumor marker analyses (PSA, hK2, PSCA, trp-p8) in primary prostate cancers using quantitative RT-PCR.

M. Wirth, A. Meye, S. Fuessel, 2003, International journal of oncology.

Detection of circulating tumor cells from renal carcinoma patients: experiences of a two-center study.

M. Wirth, H. Taubert, A. Meye, 2005, Oncology reports.

Transcript quantification of Dresden G protein-coupled receptor (D-GPCR) in primary prostate cancer tissue pairs.

E. Rieber, M. Wirth, A. Meye, 2006, Cancer letters.

Functional analyses of C13orf19/P38IP in prostate cell lines.

M. Wirth, A. Meye, S. Fuessel, 2006, Oncology reports.